AXDX - Accelerate Diagnostics, Inc.
| Previous Close | 19.88 |
| Open | 19.85 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 19.75 - 20.25 |
| 52 Week Range | 10.23 - 25.35 |
| Volume | 118,070 |
| Avg. Volume | 376,110 |
| Market Cap | 1.087B |
| Beta (3Y Monthly) | 4.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.67 |
- Markit•9 days ago
See what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDXView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AXDX had net inflows of $1.13 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•12 days ago
Accelerate Diagnostics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
TUCSON, Ariz., March 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) announced today that the company is scheduled to present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 8:40 AM Eastern Time. Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
- GuruFocus.com•20 days ago
Accelerate Diagnostics Inc (AXDX) Files 10-K for the Fiscal Year Ended on December 31, 2018
Accelerate Diagnostics Inc (AXDX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Accelerate Diagnostics Inc is an in vitro diagnostics company, dedicated in providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Warning! GuruFocus has detected 4 Warning Signs with MMI.
- Simply Wall St.•23 days ago
Should You Be Pleased About The CEO Pay At Accelerate Diagnostics, Inc.’s (NASDAQ:AXDX)
Larry Mehren has been the CEO of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) since 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. ThenRead More...
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of AXDX earnings conference call or presentation 19-Feb-19 9:30pm GMT
Q4 2018 Accelerate Diagnostics Inc Earnings Call
Motley Fool•29 days agoAccelerate Diagnostics Corp (AXDX) Q4 2018 Earnings Conference Call Transcript
AXDX earnings call for the period ending December 31, 2018.
- Associated Press•29 days ago
Accelerate Diagnostics: 4Q Earnings Snapshot
TUCSON, Ariz. (AP) _ Accelerate Diagnostics Inc. (AXDX) on Tuesday reported a loss of $22.2 million in its fourth quarter. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 41 cents per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
- PR Newswire•29 days ago
Accelerate Diagnostics Reports 2018 Fourth Quarter and Full-Year Financial Results
TUCSON, Ariz. , Feb. 19, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced financial results for the fourth quarter and fiscal year ended December 31 , 2018. "I am ...
- ACCESSWIRE•last month
Accelerate Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 ...
- Zacks•last month
Earnings Preview: Accelerate Diagnostics (AXDX) Q4 Earnings Expected to Decline
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•last month
Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax — New Research Emphasizes Economic Growth
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•last month
Accelerate Diagnostics schedules call to review 2018 fourth quarter and full-year results
TUCSON, Ariz. , Feb. 5, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, February 19, 2019 at 4:30 p.m. Eastern Time to review 2018 ...
- PR Newswire•3 months ago
Accelerate Diagnostics to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
TUCSON, Ariz., Jan. 2, 2019 /PRNewswire/ -- Accelerate Diagnostics announced today that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 2:30 PM Pacific Time. About Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc. (AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
- Simply Wall St.•3 months ago
Need To Know: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
- PR Newswire•4 months ago
Accelerate Diagnostics Pledges Matching Support for Sepsis Alliance #GivingTuesday Movement to Raise Awareness of Sepsis as a Medical Emergency
TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. has joined with Sepsis Alliance to celebrate #GivingTuesday, November 27th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. Accelerate Diagnostics has pledged to match the first $15,000 donated to Sepsis Alliance on #GivingTuesday to help raise awareness of sepsis as an often preventable medical emergency and improve outcomes for patients affected by sepsis through expanded healthcare provider education. Any infection can lead to sepsis, which is now the third leading cause of death in the United States.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of AXDX earnings conference call or presentation 6-Nov-18 9:15pm GMT
Q3 2018 Accelerate Diagnostics Inc Earnings Call
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within CSS Industries, Accelerate Diagnostics, Oasis Petroleum, Model N, Carbonite, and Masonite International — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•4 months ago
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
